Ras proteins are essential mediators of a multitude of cellular processes, and its
deregulation is frequently associated with cancer appearance, progression, and metastasis …

The Ras family of small Guanosine Triphosphate (GTP)-binding proteins (G proteins)
represents one of the main components of intracellular signal transduction required for …

Targeting specific protein–protein interactions (PPIs) is an attractive concept for drug
development, but hard to implement since intracellular antibodies do not penetrate cells and …

RAS oncogenes are among the most commonly mutated proteins in human cancers. They
regulate a wide range of effector pathways that control cell proliferation, survival …

In this review, we analyse the impact of oncogenic Ras mutations in mediating cancer drug
resistance and the progress made in the abrogation of this resistance, through …

RAS effectors specifically interact with the GTP-bound form of RAS in response to
extracellular signals and link them to downstream signaling pathways. The molecular nature …

RAS belongs to the super family of small G proteins and plays crucial roles in signal
transduction from membrane receptors in the cell. Mutations of K-RAS oncogene lead to an …

Despite decades of extensive drug discovery efforts, there are currently no targeted
therapies approved to treat KRAS mutant cancers. In this review, we highlight the challenges …

Kirsten rat sarcoma virus (KRAS) is one of the most important and frequently mutated
oncogenes in cancer and the mutational prevalence is especially high in many …

RAF (rapidly accelerated fibrosarcoma) Ser/Thr kinases (ARAF, BRAF, and CRAF) link the
RAS (rat sarcoma) protein family with the MAPK (mitogen-activated protein kinase) pathway …